tbuckley/cabot-search huggingface dataset:
Novel Capsid Assembly Effectors Inhibit Hbv Cccdna Formation in an Hbeag Reporter Cell-Based Assay
Authors: L. Bassit, S. Boucle, F. Amblard, L. Zhou, H.W. Zhang, H.-M. Hsiao, T. Ozturk, O. Russell, R.F. Schinazi
Journal: Journal of Hepatology (2016)
Contrast induced nephropathy predicts later mortality among patients with non-ST-segment elevation acute coronary syndrome undergoing PCI: a sub-analysis from the EARLY ACS study
Authors: G. M De Ferrari, Frans Van de Werf, P Armstrong, C Bode, B. S Lewis, P Tricoci, Jia Guo, C Contant, K Newby, R. P Giugliano
Journal: American Journal of Respiratory and Critical Care Medicine (2011)
Tissue biomarkers in colon cancer (COC): The translational study on a phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II-III COC patients (PETACC 3-EORTC 40993-SAKK 60/00)
Authors: A Roth, Sabine Tejpar, P Yan, R Rocca, Dietrich Hectors, S Hsu Schmitz, C Barone, G Bodoky, R Labianca, D Cunningham, Eric Van Cutsem, F Bosman
Journal: Annals of Oncology (2007)
Prospective Randomized Controlled Phase III Trial Comparing the Efficacy of Sorafenib versus Sorafenib in Combination with Low-Dose Cisplatin/Fluorouracil Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma
Authors: M. Kudo, K. Ueshima, O. Yokosuka, S. Obi, N. Izumi, H. Aikata, H. Nagano, E. Hatano, Y. Sasaki, K. Hino, T. Kumada, K. Yamamoto, Y. Imai, S. Iwadou, C. Ogawa, T. Okusaka, Y. Arai, F. Kanai, K. Akazawa
Journal: Journal of Hepatology (2016)
Safety of Direct-Acting Antivirals-Based Therapy for the Treatment of Patients with Chronic Hepatitis C Virus Infection and Cirrhosis: Results from an International Multicenter Cohort Study
Authors: R. Maan, M. van Tilborg, K. Deterding, A. Ramji, A.J. van der Meer, F. Wong, S. Fung, M. Sherman, M.P. Manns, M. Cornberg, H. Wedemeyer, H.L. Janssen, R.J. de Knegt, J.J. Feld
Journal: Journal of Hepatology (2016)
Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease
Authors: Karim Gariani, Dongryeol Ryu, Keir J. Menzies, Hyon-Seung Yi, Sokrates Stein, Hongbo Zhang, Alessia Perino, Vera Lemos, Elena Katsyuba, Pooja Jha, Sandrine Vijgen, Laura Rubbia-Brandt, Yong Kyung Kim, Jung Tae Kim, Koon Soon Kim, Minho Shong, Kristina Schoonjans, Johan Auwerx
Journal: Journal of Hepatology (2016)

To date, no pharmacological therapy has been approved for non-alcoholic fatty liver disease (NAFLD). The aim of the present study was to evaluate the therapeutic potential of poly ADP-ribose polymerase (PARP) inhibitors in mouse models of NAFLD.As poly ADP-ribosylation (PARylation) of proteins by PARPs consumes nicotinamide adenine dinucleotide (NAD+), we hypothesized that overactivation of PARPs drives NAD+ depletion in NAFLD. Therefore, we assessed the effectiveness of PARP inhibition to replenish NAD+ and activate NAD+-dependent sirtuins, hence improving hepatic fatty acid oxidation. To do this, we examined the preventive and therapeutic benefits of the PARP inhibitor (PARPi), olaparib, in different models of NAFLD.The induction of NAFLD in C57BL/6J mice using a high-fat high-sucrose (HFHS)-diet increased PARylation of proteins by PARPs. As such, increased PARylation was associated with reduced NAD+ levels and mitochondrial function and content, which was concurrent with elevated hepatic lipid content. HFHS diet supplemented with PARPi reversed NAFLD through repletion of NAD+, increasing mitochondrial biogenesis and β-oxidation in liver. Furthermore, PARPi reduced reactive oxygen species, endoplasmic reticulum stress and fibrosis. The benefits of PARPi treatment were confirmed in mice fed with a methionine- and choline-deficient diet and in mice with lipopolysaccharide-induced hepatitis; PARP activation was attenuated and the development of hepatic injury was delayed in both models. Using Sirt1hep-/- mice, the beneficial effects of a PARPi-supplemented HFHS diet were found to be Sirt1-dependent.Our study provides a novel and practical pharmacological approach for treating NAFLD, fueling optimism for potential clinical studies.Non-alcoholic fatty liver disease (NAFLD) is now considered to be the most common liver disease in the Western world and has no approved pharmacological therapy. PARP inhibitors given as a treatment in two different mouse models of NAFLD confer a protection against its development. PARP inhibitors may therefore represent a novel and practical pharmacological approach for treating NAFLD.
The Immerging Role of Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma - A Case Series
Authors: A. Moore, A. Allen, Y. Kundel, O. Benjaminov, M. Broun, A. Issachar, E. Mor, A. Tovar, N. Gordon, S.M. Shtemer, M. Cohen
Journal: Journal of Hepatology (2016)
Transient Elastography and Combination of Fibrotest® and Transient Elastography for Diagnosis of Advanced Fibrosis and Cirrhosis in Patients with Alcoholic Liver Disease: A Prospective Multicenter Cohort Study
Authors: C.S. Voican, A. Louvet, J.-B. Trabut, M. Njiké-Nakseu, S. Dharancy, A. Sanchez, M. Corouge, K. Lamouri, A. Lebrun, A. Balian, S. Prévot, M. Lachgar, S. Maitre, H. Agostini, P. Mathurin, G. Perlemuter, S. Naveau
Journal: Journal of Hepatology (2016)
Streptokinase in Acute Myocardial Infarction
Journal: New England Journal of Medicine (1979)

In a controlled trial of streptokinase in acute myocardial infarction, 512 of 2338 patients at 11 European centers were stratified according to clinical severity. Three hundred fifteen patients allocated to medium-risk and high-risk groups were randomized to a 24-hour infusion of streptokinase or glucose. There were no essential differences in the severity of illness in the two groups before infusion. The overall mortality rates within six months were significantly lower (P less than 0.01) in the streptokinase group (15.6 per cent) than in the control group (30.6 per cent). Bleeding complications were more frequent in the streptokinase group; except for two nonfatal cerebral hemorrhages these complications were clinically unimportant. The treatment was generally well tolerated. We tolerated. We conclude that streptokinase given under the conditions of this trial -- to medium-risk patients admitted to a coronary-care unit within 12 hours of onset of symptoms -- reduces mortality at six months. (N Engl J Med 301:797-802, 1979)
Coltuximab Ravtansine (SAR3419) Demonstrates Enhanced Activity in Combination with Bendamustine, Gemcitabine and Novel Targeted Agents Such As PI3K Inhibitors in Pre-Clinical Models of Relapsed and/or Refractory Non-Hodgkins Lymphoma (NHL)
Authors: Callum M Sloss, Katie O'Callaghan, Jutta Deckert, Jenny Tsui, Leanne Lanieri, Angela Romanelli
Journal: Blood (2015)
Safety of ABT-493 and ABT-530 Co-Administered in Patients with HCV Genotype 1–6 Infection: Results from the Surveyor-I and Surveyor-II Studies
Authors: P. Kwo, F. Poordad, A. Porcalla, E. Gane, J. Lalezari, D. Wyles, R. Liu, J. Kort, F.J. Mensa
Journal: Journal of Hepatology (2016)
CaMKII Phosphorylation of TARPγ-8 Is a Mediator of LTP and Learning and Memory
Authors: Joongkyu Park, Andrés E. Chávez, Yann S. Mineur, Megumi Morimoto-Tomita, Stefano Lutzu, Kwang S. Kim, Marina R. Picciotto, Pablo E. Castillo, Susumu Tomita
Journal: Neuron (2016)
Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study
Authors: Ygal Benhamou, Gilles Paintaud, Elie Azoulay, Pascale Poullin, Lionel Galicier, Céline Desvignes, Jean‐Luc Baudel, Julie Peltier, Jean‐Paul Mira, Frédéric Pène, Claire Presne, Samir Saheb, Christophe Deligny, Alexandra Rousseau, Frédéric Féger, Agnès Veyradier, Paul Coppo
Journal: American Journal of Hematology (2016)

The standard four-rituximab infusions treatment in acquired thrombotic thrombocytopenic purpura (TTP) remains empirical. Peripheral B cell depletion is correlated with the decrease in serum concentrations of anti-ADAMTS13 and associated with clinical response. To assess the efficacy of a rituximab regimen based on B cell depletion, 24 TTP patients were enrolled in this prospective multicentre single arm phase II study and then compared to patients from a previous study. Patients with a suboptimal response to a plasma exchange-based regimen received two infusions of rituximab 375 mg m-2 within 4 days, and a third dose at day +15 of the first infusion if peripheral B cells were still detectable. Primary endpoint was the assessment of the time required to platelet count recovery from the first plasma exchange. Three patients died after the first rituximab administration. In the remaining patients, the B cell-driven treatment hastened remission and ADAMTS13 activity recovery as a result of rapid anti-ADAMTS13 depletion in a similar manner to the standard four-rituximab infusions schedule. The 1-year relapse-free survival was also comparable between both groups. A rituximab regimen based on B cell depletion is feasible and provides comparable results than with the four-rituximab infusions schedule. This regimen could represent a new standard in TTP. This trial was registered at www.clinicaltrials.gov (NCT00907751). Am. J. Hematol. 91:1246-1251, 2016. © 2016 Wiley Periodicals, Inc.
Array-CGH mapping of an overrepresented 7Q region in gamma/delta hepatosplenic T-cell lymphoma
Authors: Iwona Wlodarska, H Urbankova, Peter Van Loo, S Shetty, B Roland, L Krenacs, P De Paepe, Jaak Billiet, M Jarosova, Peter Vandenberghe, Christiane Peeters
Journal: Annals of Oncology (2008)
Need and timing of kidney transplantation in relation to liver transplantation in polycystic liver disease
Authors: Frederik Temmerman, Tom Darius, Jacques Pirenne, Diethard Monbaliu, Raymond Aerts, Bert Bammens, Wim Laleman, David Cassiman, Chris Verslype, Werner Van Steenbergen, Dirk Kuypers, Frederik Nevens
Journal: Hepatology (2011)
Population-Based Factors Associated with Early Death after Liver Cancer Diagnosis and Resection in Queensland, Australia 1996-2011
Authors: P.J. Clark, T.R. O’Rourke, J. Fawcett, K.A. Stuart, G.A. Macdonald, D.H. Crawford, B.A. Leggett, D.C. Whiteman, P.A. Baade, P.C. Valery
Journal: Journal of Hepatology (2016)
Sustained Virological Responses (SVR) of 97% in Genotype 2 (GT-2) Patients with F3/4 Stage of Fibrosis Treated with Sofosbuvir (SOF) and Weight-Based Ribavirin (RBV): A Real Life, Single Centre Experience
Authors: A. Mangia, A. Arleo, V. Piazzolla, R. Santoro, D. Petruzzellis, M. Miscio, M.M. Squillante
Journal: Journal of Hepatology (2016)
Abstract A40: Megakaryocyte endomitosis requires Pak2 to regulate actin and microtubule networks.
Authors: Rachelle E. Kosoff, Jonathan Chernoff
Journal: Clinical Cancer Research (2015)

Abstract Megakaryocytes mature and differentiate into polyploid cells in the bone marrow, and migrate from the osteoblastic niche to the vascular niche by means of an SDF-1α gradient, culminating in the release of platelets into circulation. Failure to do so results in myeloproliferative disorders, which can manifest as thrombocytopenia. Many chemotherapeutic agents are known to induce thrombocytopenia and other platelet disorders. Regulation of megakaryocyte differentiation and polyploidization is controlled by MAPK associated proteins, and cytoskeleton regulating proteins. p21-activated kinase 2 (Pak2) is known to regulate these two pathways, but nothing is currently known about the role of Pak2 in megakaryocyte biology. In our study, we sought to demonstrate that Pak2 is essential for proper megakaryocyte differentiation, maturation and polyploidization, in vivo and in vitro. Inducible deletion of Pak2fl/fl results in 100% lethality within 20 days of cre induction, specifically in hematopoietic tissues (Mx1-cre). Peripheral blood analysis demonstrates thrombocytopenia (reduced platelet counts), along with increased neutrophil count (neutrophilia) and decreased lymphocyte count. Bone marrow histology and analysis by flow cytometry demonstrates altered megakaryocyte differentiation, observed by elevated megakaryocyte(Mk) precursors in the bone marrow (Lin-ckit+Sca1- CD150+CD41+), elevated mature bone marrow Mks (CD41+), increased number of polyploid cells(&amp;gt;8N) and hyperplastic megakaryocytes. In vitro culture of bone marrow derived Pak2-null megakaryocytes demonstrates elevated polyploidization, altered β1-tubulin structure and reduced platelet formation. Additionally, cre activation in platelets and megakaryocytes using a PF4-cre driver (platelet factor 4) recapitulates the enhanced polyploidization phenotype observed in the Mx1-cre model. Ultimately, we demonstrate that Pak2 signals through LIMK, cofilin, and myosin light chain 2 (MLC2) to regulate megakaryocyte cytoskeleton during differentiation and polyploidization. In summary, Pak2 is an important regulator of megakaryocyte maturation and platelet formation in vivo via regulation of proteins involved in cytoskeletal dynamics. Citation Format: Rachelle E. Kosoff, Jonathan Chernoff. Megakaryocyte endomitosis requires Pak2 to regulate actin and microtubule networks. [abstract]. In: Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(17 Suppl):Abstract nr A40.
O108 : Residual HCV-RNA in liver explants from patients undergoing sofosbuvir and ribavirin treatment while awaiting liver transplantation is not associated with HCV relapse
Authors: M. Gambato, S. Pérez-del-Pulgar, C. Hedskog, J. Svarovskia, M.S. Paulson, J. Denning, M.P. Curry, N. Caro-Pérez, M.C. Londoño, X. Forns
Journal: Journal of Hepatology (2015)
Phase IIa Study of Single-Agent MOR208 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Authors: Wojciech Jurczak, Pier Luigi Zinzani, Gianluca Gaidano, Andre Goy, Mariano Provencio, Zsolt Nagy, Tadeusz Robak, Kami J. Maddocks, Christian Buske, Roman Pawel Korolkiewicz, Frank Striebel, Kristie Blum
Journal: Blood (2015)
Early Evaluation of Alpha-Fetoprotein Response for Predicting Outcomes in Sorafenib Treated Patients May be Misleading
Authors: G.G. Di Costanzo, R. Tortora, G. Cordone, M. Guarino, M.T. Tartaglione, M. De Luca, F.P. Picciotto, L. Falco, F. Morisco, N. Caporaso
Journal: Journal of Hepatology (2016)
Allogeneic Hematopoietic Stem Cell Transplantation in HIV-Positive Patients with High Risk Hematologic Malignancies
Authors: David Serrano, Rafael Carrión, Pilar Miralles, Gabriela Rodriguez-Macias, Jorge Gayoso, Juan Berenguer, Javier Anguita, Mi Kwon, Pascual Balsalobre, Gomez-Pineda Alfonso, Ismael Buno, Jose L. Diez-Martin
Journal: Blood (2008)
Mice deficient in growth arrest specific gene 6 (Gas6) show increased hemorrhage in atherosclerosis, myocardial infarction and after LPS-footpad injection and exhibit increased VEGF induced capillary hyperpermeability
Authors: E Lutgens, Lieve Moons, PG de Frutos, C Aparicio, M Blankensteijn, M Borgers, JM Herbert, B Dahlback, Desire Collen, MJ Daemen, Peter Carmeliet
Journal: Circulation (2003)
A rapid and sensitive liquid chromatography–tandem mass spectrometric method for the determination of hederasaponin B in rat plasma: Application to a pharmacokinetic study
Authors: Jiaxin Liu, Xueyan Yang, Lin Li, Qili Zhang, Zhaoyan Zhang, Xin Zhang, Yunli Zhao, Miao Yu, Zhiguo Yu
Journal: Asian Journal of Pharmaceutical Sciences (2016)

A rapid, simple and sensitive ultra-high performance liquid chromatography-tandem mass spectrometric (UPLC-MS/MS) method was developed and validated for the determination of hederasaponin B, an active triterpenoid saponin widely existed in Hedera helix L. Plasma samples were processed by protein precipitation with acetonitrile and separated on a Thermo Hypersil GOLD C18 (2.1 mm × 50 mm,1.9 µm) at flow rate of 0.3 ml/min, with a gradient elution consisting of acetonitrile and water containing 0.1% (v/v) formic acid at 30 °C and detected by electrospray ionization mass spectrometry in the positive multiple reaction monitoring (MRM) mode. The linearity was found to be within the concentration range of 0.5-5000 ng/ml with a lower limit of quantification of 0.5 ng/ml. The absolute oral bioavailability of hederasaponin B was 0.24 ± 0.49%. This indicated that the concentration-time course of the hederasaponin B existed a double-peak phenomenon. This method was further applied to the determination of hederasaponin B in rat plasma and showed good practicability, for the first time, after intragastric (25 mg/kg) and intravenous (2 mg/kg) administration in rats.
Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium
Authors: Elias Jabbour, Koji Sasaki, Mikkael A. Sekeres, Rami S Komrokji, David P. Steensma, Amy E. DeZern, Roboz J Gail, Naval G. Daver, Naveen Pemmaraju, Tapan Kadia, Courtney D. DiNardo, Xuemei Wang, Graciela Nogueras-Gonzalez, Gautam Borthakur, Zeev Estrov, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2014)
Pro-Euro-Dili Registry: A Collaborative Effort to Enhance the Understanding of Dili
Authors: M. Slim, C. Stephens, M. Robles-Díaz, I. Medina-Caliz, J.I. Grove, A. Ortega-Alonso, M.I. Lucena, G.P. Aithal, R.J. Andrade
Journal: Journal of Hepatology (2016)
In Vivo Myofibroblast Specific Gene Silencing in the Liver Using Novel Sirna-Loaded Biodegradable Nanohydrogel Particles
Authors: L. Kaps, L. Nuhn, M. Aslam, A. Brose, F. Foerster, R. Zentel, D. Schuppan
Journal: Journal of Hepatology (2016)
Abstract 20579: Chronic Kidney Disease is Associated With Increased Mortality and Major Adverse Cardiovascular Events in Patients With Peripheral Arterial Disease
Authors: Gregory G Westin, Ehrin J Armstrong, Debbie C Chen, John R Laird
Journal: Circulation (2014)

Introduction: Chronic kidney disease (CKD) is common in patients with peripheral arterial disease (PAD), but patients with severe CKD have been excluded from many trials and no objective performance goals exist for patients with PAD and CKD. We sought to analyze the association between severity of CKD and cardiovascular and limb-related outcomes among patients with PAD. Methods: We reviewed records of all patients at our institution who underwent lower extremity angiography between 2006 and 2013. We analyzed outcomes including mortality, major adverse cardiovascular event (MACE) rate, and major adverse limb event (MALE) rate according to clinical stage of CKD, determined by calculating each patient’s glomerular filtration rate using the Cockcroft-Gault equation. We used Cox proportional hazard modeling to account for covariates, along with Bonferroni correction for multiple comparisons. Results: Of 773 patients, 45% had CKD stage 3-5. The patients had a median age of 67, were 58% male, 51% diabetic, and 57% presented with critical limb ischemia (CLI). During a median follow-up time of 3.2 years, patients with higher stages of CKD had an increased rate of death (Figure 1, p&lt;0.001). CKD stages 4 and 5 were significant predictors of mortality in a multivariate model (HR 3.2 and 2.4 vs. CKD 1, P&lt;0.001 and P&lt;0.01, respectively). An analysis of MACE by CKD stage demonstrated similar results (CKD 4 HR 2.2, p&lt;0.01; CKD 5 HR 2.0, p&lt;0.01). CKD stage also predicted MALE in a univariate analysis (p&lt;0.01), driven by increased limb events among patients with CKD stage 5 (p&lt;0.01). However, CKD stage did not demonstrate a significantly increased hazard of MALE in a multivariate Cox model. Conclusions: Patients with PAD who also have CKD have increased rates of adverse outcomes. This relationship seems to be more robust for major cardiovascular events and overall mortality than for major limb events. Future studies should investigate how management of PAD should differ for patients with CKD.
The scaffolding function of the RLTPR protein explains its essential role for CD28 co-stimulation in mouse and human T cells
Authors: Romain Roncagalli, Margot Cucchetti, Nicolas Jarmuzynski, Claude Grégoire, Elise Bergot, Stéphane Audebert, Emilie Baudelet, Marisa Goncalves Menoita, Anais Joachim, Stéphane Durand, Miloslav Suchanek, Frédéric Fiore, Lichen Zhang, Yinming Liang, Luc Camoin, Marie Malissen, Bernard Malissen
Journal: The Journal of Experimental Medicine (2016)

The RLTPR cytosolic protein, also known as CARMIL2, is essential for CD28 co-stimulation in mice, but its importance in human T cells and mode of action remain elusive. Here, using affinity purification followed by mass spectrometry analysis, we showed that RLTPR acts as a scaffold, bridging CD28 to the CARD11/CARMA1 cytosolic adaptor and to the NF-κB signaling pathway, and identified proteins not found before within the CD28 signaling pathway. We further demonstrated that RLTPR is essential for CD28 co-stimulation in human T cells and that its noncanonical pleckstrin-homology domain, leucine-rich repeat domain, and proline-rich region were mandatory for that task. Although RLTPR is thought to function as an actin-uncapping protein, this property was dispensable for CD28 co-stimulation in both mouse and human. Our findings suggest that the scaffolding role of RLTPR predominates during CD28 co-stimulation and underpins the similar function of RLTPR in human and mouse T cells. Along that line, the lack of functional RLTPR molecules impeded the differentiation toward Th1 and Th17 fates of both human and mouse CD4+ T cells. RLTPR was also expressed in both human and mouse B cells. In the mouse, RLTPR did not play, however, any detectable role in BCR-mediated signaling and T cell-independent B cell responses.
Low Dose Subcutaneous Alemtuzumab and Preemptive Donor Lymphocyte Infusion without Withdrawal of Immunosuppression Results in Low Non-Relapse Mortality, Decreased Hospitalization, and Favorable Outcomes for High Risk Older Recipients of Unrelated Donor Allogeneic Transplants: A Prospective Phase II Trial
Authors: Connie A. Sizemore, Asad Bashey, Karen Manion, H. Kent Holland, Lawrence E. Morris, Stacey Brown, Xu Zhang, Scott R. Solomon
Journal: Blood (2011)